Elevating Equitable Health Care for the LGBTQ+ Community
June 18th 2024For the third episode in our special Pride Month series, we speak with Patrick McGovern, CEO of Callen-Lorde since August of 2023 and an outspoken advocate for HIV; lesbian, gay, bisexual, transgender, queer, plus (LGBTQ+); and community health.
Listen
STRONG-HF Data Suggest Bio-ADM Enhances Heart Failure Prognostic Value
June 17th 2024Patients with the highest biologically active adrenomedullin (bio-ADM) levels at baseline were 114% more likely to die from any cause or be readmitted to the hospital for heart failure within 6 months compared with patients with the lowest levels.
Read More
What We’re Reading: Aging With HIV; Obesity Treatment Barriers; Social Media Warning Labels
June 17th 2024Ageing with HIV comes with greater risks of other health complications; behavioral counseling programs for obesity are scare and often not covered by insurance; the surgeon general is calling for legislative action to protect youth when they interact with social media.
Read More
Polatuzumab Vedotin: Review Spotlights Its Use, Promise in DLBCL
June 17th 2024With its recent approvals around the world to treat newly diagnosed and relapsed/refractory diffuse large B-cell lymphoma (DLBCL), the antibody-drug conjugate polatuzumab vedotin is changing regimens for current and future patients, with manageable adverse effects.
Read More
Late-Breaking Abstracts at EHA 2024 Span From the Clinic to the Proteome to the Andes Mountains
June 16th 2024The late-breaking oral session at the European Hematology Association (EHA) 2024 Congress featured new data from abstracts submitted after the deadline, including both interventional and foundational science.
Read More
Tislelizumab Plus Chemo Meaningfully Improves OS, PFS in Advanced Esophageal Cancer
June 14th 2024The results of the 3-year follow-up show meaningful improvement in overall survival (OS) and progression-free survival (PFS) for tislelizumab plus chemotherapy compared with placebo plus chemotherapy.
Read More
Encouraging Data Emerge for Outpatient CAR T-Cell Treatment of Lymphoma
June 14th 2024Results presented at the 2024 European Hematology Association Congress suggest that chimeric antigen receptor (CAR) T-cell therapy can be feasibly and safely delivered in the outpatient setting as treatment for lymphoma.
Read More
The arrests of the founders of Done Global, a telehealth company that provides attention-deficit/hyperactivity disorder (ADHD) medication to adults, for allegedly providing prescriptions to unqualified patients and defrauding the government have raised concerns about future access to these medications; US health care spending rose to $4.8 trillion in 2023; bipartisan legislation has been introduced to reform prior authorization with Medicare Advantage.
Read More
Reducing Waste in Hematology Starts With the New Generation of Researchers and Clinicians
June 14th 2024At a YoungEHA session at the 2024 European Hematology Association (EHA) Congress, speakers discussed the prevalence of waste in laboratories, research, and clinical practice, as well as ways attendees can effect change for a more sustainable future.
Read More
Link Between Skin Cancer and Immunosuppressants Needs Further Research
June 13th 2024At the 2024 American Society of Clinical Oncology annual meeting, an abstract presenting real-world data stressed the need for further research regarding the association between immunosuppressant medication and the development of skin cancer.
Read More